Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 25, Number 7—July 2019
Synopsis

Carbapenem-Resistant Pseudomonas aeruginosa at US Emerging Infections Program Sites, 2015

Maroya Spalding WaltersComments to Author , Julian E. Grass, Sandra N. Bulens, Emily B. Hancock, Erin C. Phipps, Daniel Muleta, Jackie Mounsey, Marion A. Kainer, Cathleen Concannon, Ghinwa Dumyati, Chris Bower, Jesse Jacob, P. Maureen Cassidy, Zintars Beldavs, Karissa Culbreath, Walter E. Phillips, Dwight J. Hardy, Roberto L. Vargas, Margret Oethinger, Uzma Ansari, Richard Stanton, Valerie Albrecht, Alison Laufer Halpin, Maria Karlsson, J. Kamile Rasheed, and Alexander Kallen
Author affiliations: Centers for Disease Control and Prevention, Atlanta, Georgia, USA (M.S. Walters, J.E. Grass, S.N. Bulens, U. Ansari, R. Stanton, V. Albrecht, A.L. Halpin, M. Karlsson, J.K. Rasheed, A. Kallen); New Mexico Emerging Infections Program, Santa Fe, New Mexico, USA (E.B. Hancock, E.C. Phipps); University of New Mexico, Albuquerque, New Mexico, USA (E.B. Hancock, E.C. Phipps, K. Culbreath); Tennessee Department of Public Health, Nashville, Tennessee, USA (D. Muleta, J. Mounsey, M.A. Kainer); University of Rochester, Rochester, New York, USA (C. Concannon, G. Dumyati, D.J. Hardy); Atlanta Veterans Affairs Medical Center, Decatur, Georgia, USA (C. Bower); Atlanta Research and Education Foundation, Decatur (C. Bower); Georgia Emerging Infections Program, Atlanta (C. Bower, J. Jacob); Emory University School of Medicine, Atlanta (J. Jacob); Oregon Health Authority, Portland, Oregon, USA (P.M. Cassidy, Z. Beldavs); TriCore Reference Laboratories, Albuquerque (K. Culbreath); Tristar Centennial Medical Center, Nashville (W.E. Phillips, Jr.); Rochester Regional Health, Rochester (R.L. Vargas); Providence Health and Services, Renton, Washington, USA (M. Oethinger)

Main Article

Table 1

Carbapenem-resistant Pseudomonas aeruginosa isolates identified through Emerging Infections Program sites, United States, July–October 2015*

Site No. carbapenem-resistant P. aeruginosa isolates Total no. P. aeruginosa isolates % Carbapenem resistant No. incident cases†
Georgia 68 566 12.0 49
Tennessee 91 890 10.2 79
New Mexico 116 1,295 9.0 85
New York‡ 83 932 8.9 60
Oregon
 26
 560
 4.6
 21
Total 384 4,243 9.1 294

*Isolates are P. aeruginosa isolated from any specimen source except nares, rectum, perirectal area, or feces; carbapenem-resistant P. aeruginosa are isolates resistant to >1 carbapenem with anti-pseudomonal activity (doripenem, imipenem, or meropenem).
†Incident case defined as first carbapenem-resistant P. aeruginosa case in a patient in a 30-day period.
‡Cases in New York were identified through population-based surveillance; all other sites performed sentinel surveillance.

Main Article

Page created: June 17, 2019
Page updated: June 17, 2019
Page reviewed: June 17, 2019
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external